Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis
暂无分享,去创建一个
H. Kantarjian | J. Cortes | S. Verstovsek | N. Daver | N. Pemmaraju | L. Masarová | S. Pierce | P. Bose | Ahmad Alhuraiji
[1] M. Ramírez,et al. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia , 2018, British journal of haematology.
[2] H. Kantarjian,et al. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. , 2015, Leukemia research.
[3] T Giorgino,et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis , 2017, Leukemia.
[4] H. Kantarjian,et al. Clinical features and outcome of patients with poor-prognosis myelofibrosis based on platelet count <50 x 109/L: A single-center experience in 1100 myelofibrosis patients. , 2016 .
[5] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[6] H. Hasselbalch,et al. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients , 2016, Leukemia & lymphoma.
[7] H. Deeg,et al. Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] R. Laborde,et al. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. , 2015, The New England journal of medicine.
[9] Arturo Pereira,et al. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis , 2014, Haematologica.
[10] H. Kantarjian,et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring , 2014, Haematologica.
[11] H. Kantarjian,et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts , 2013, Journal of Hematology & Oncology.
[12] S. Bosari,et al. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis , 2012, Modern Pathology.
[13] A. Mead,et al. Guideline for the diagnosis and management of myelofibrosis , 2012, British journal of haematology.
[14] Jason Gotlib,et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.
[15] M. Cazzola,et al. Leukemia risk models in primary myelofibrosis: an International Working Group study , 2012, Leukemia.
[16] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Tefferi,et al. Age and platelet count are IPSS‐independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival , 2010, European journal of haematology.
[18] H. Kantarjian,et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Le Bousse-Kerdilès,et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. , 2008, Blood.
[20] P. Campbell,et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment , 2008, Leukemia.
[21] Sandra A. Moore,et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.
[22] A. Tefferi. Pathogenesis of myelofibrosis with myeloid metaplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Benetatos Leonidas,et al. Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis , 2005 .
[24] A. Vassou,et al. Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis. , 2005, European Journal of Haematology.
[25] R. Mesa,et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.
[26] P. Wollan,et al. Population‐based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976–1995 , 1999, American journal of hematology.
[27] R. E. Smith,et al. Myelofibrosis: a review of clinical and pathologic features and treatment. , 1990, Critical reviews in oncology/hematology.